Mesoblast Valuation Multiples

Mesoblast Overview

About Mesoblast

Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.

Founded

2004

HQ

Employees

81

Website

mesoblast.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $104M

EBITDA: ($32M)

EV

$2B

Valuation Multiples

Multiples.vc

Start free trial

Mesoblast Financials

Mesoblast reported last 12-month revenue of $104M and negative EBITDA of ($32M).

In the same LTM period, Mesoblast generated $90M in gross profit, ($32M) in EBITDA losses, and had net loss of ($60M).

Mesoblast P&L

In the most recent fiscal year, Mesoblast reported revenue of $17M and EBITDA of ($69M).

Mesoblast expects next 12-month revenue of XXX and NTM EBITDA of XXX

Mesoblast Stock Performance

Mesoblast has current market cap of $2B, and enterprise value of $2B.

Mesoblast's stock price is $1.61.

Mesoblast Valuation Multiples

Mesoblast trades at 20.0x EV/Revenue multiple, and (66.0x) EV/EBITDA.

Mesoblast Financial Valuation Multiples

As of April 18, 2026, Mesoblast has market cap of $2B and EV of $2B.

Equity research analysts estimate Mesoblast's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Mesoblast has a P/E ratio of (34.4x).

Mesoblast Margins & Growth Rates

Mesoblast's revenue in the last 12 month grew by 95%.

Mesoblast's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.9M for the same period.

Mesoblast's rule of 40 is 153% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Mesoblast's rule of X is 369% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Mesoblast Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Mesoblast M&A Activity

Mesoblast acquired XXX companies to date.

Last acquisition by Mesoblast was on XXXXXXXX, XXXXX. Mesoblast acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Mesoblast Investment Activity

Mesoblast invested in XXX companies to date.

Mesoblast made its latest investment on XXXXXXXX, XXXXX. Mesoblast invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).